West Virginia University Logo

Disease Site: Other Cancers

9 protocol(s) meet the specified criteria

  • COG-AEWS1031COG-AEWS1031 - A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
  • COG-AEWS1221Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
  • COG-AGCT1531A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
  • COG-ANBL1531Testing the Addition of 131I-MIBG or Crizotinib to Intensive Therapy in People With High-risk Neuroblastoma (NBL)
  • COG-APEC1621NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)
  • COG-ARST1321COG-ARST1321 Pazopanib Neoadjuvant Trial in Non-Rhadomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
  • EAY131Molecular Analysis for Therapy Choice (MATCH)
  • LOXO-TRK-15002A Phase II Basket Study of Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
  • RRX001-211-01A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Lung Cancer, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Readministration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)